Stock ORNAV ORION OYJ
Add to a list
To use this feature you must be a member
Log inSign up

Financials Orion Oyj Nasdaq Helsinki

Equities

ORNAV

FI0009014369

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 13:42:05 26/06/2024 BST 		5-day change 1st Jan Change
39.62 EUR -0.06% Intraday chart for Orion Oyj +2.73% +0.89%
06-25 Orion Obtains License to Market Navamedic's Parkinson's Disease Drug in Europe MT
06-24 Navamedic ASA and Orion Corporation Sign License & Supply Agreement for Flexilev in Europe CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,786 5,267 5,119 7,179 5,509 5,594 - -
Enterprise Value (EV) 1 5,647 5,081 5,010 7,060 5,603 5,593 5,621 5,593
P/E ratio 28.9 x 24.1 x 26.5 x 20.6 x 25.5 x 23.1 x 22.6 x 17.4 x
Yield 3.63% 4% 4.11% 3.12% 4.13% 4.17% 4.29% 4.45%
Capitalization / Revenue 5.51 x 4.89 x 4.92 x 5.36 x 4.63 x 4.06 x 3.85 x 3.46 x
EV / Revenue 5.37 x 4.71 x 4.81 x 5.27 x 4.71 x 4.06 x 3.87 x 3.45 x
EV / EBITDA 18.3 x 15.1 x 17.3 x 14.5 x 17.2 x 15.3 x 15.2 x 12.1 x
EV / FCF 24.7 x 20.3 x 38.5 x 21.7 x 105 x 31.6 x 28 x 25.7 x
FCF Yield 4.04% 4.93% 2.6% 4.6% 0.95% 3.17% 3.57% 3.88%
Price to Book 7.44 x 7.2 x 6.86 x 7.91 x 6.19 x 6.14 x 6.08 x 5.51 x
Nbr of stocks (in thousands) 140,492 140,463 140,563 140,202 140,351 140,501 - -
Reference price 2 41.27 37.53 36.52 51.24 39.27 39.87 39.87 39.87
Announcement Date 05/02/20 09/02/21 10/02/22 09/02/23 13/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,051 1,078 1,041 1,341 1,190 1,377 1,453 1,619
EBITDA 1 308.9 336.5 289.1 487.1 326.4 365.7 368.8 461.4
EBIT 1 252.8 280.1 243.3 439.6 274.9 309.5 306.1 409.5
Operating Margin 24.05% 25.98% 23.37% 32.79% 23.11% 22.48% 21.07% 25.3%
Earnings before Tax (EBT) 1 250.8 278.3 242.3 440.3 271.9 307.9 311.4 406.6
Net income 1 200.4 219.9 193.8 349.5 216.8 242.8 247.9 323.3
Net margin 19.07% 20.4% 18.62% 26.07% 18.22% 17.63% 17.06% 19.97%
EPS 2 1.430 1.560 1.380 2.490 1.540 1.727 1.762 2.297
Free Cash Flow 1 228.2 250.6 130.3 324.8 53.4 177.1 200.7 217.2
FCF margin 21.71% 23.24% 12.52% 24.23% 4.49% 12.86% 13.82% 13.42%
FCF Conversion (EBITDA) 73.88% 74.47% 45.07% 66.68% 16.36% 48.42% 54.42% 47.08%
FCF Conversion (Net income) 113.87% 113.96% 67.23% 92.93% 24.63% 72.92% 80.97% 67.19%
Dividend per Share 2 1.500 1.500 1.500 1.600 1.620 1.663 1.710 1.773
Announcement Date 05/02/20 09/02/21 10/02/22 09/02/23 13/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 276.5 270.6 283.7 491.8 294.5 277.9 289.6 301.1 321.1 308.5 320.6 365.2 394.2
EBITDA 1 52.6 83 93.6 257.4 53.2 67.7 59.2 93.5 106 68.5 70.9 132.4 99.27
EBIT 1 39.9 71.5 82 245.4 40.7 55.5 46.5 80 92.9 56 57.72 107.2 93.57
Operating Margin 14.43% 26.42% 28.9% 49.9% 13.82% 19.97% 16.06% 26.57% 28.93% 18.15% 18% 29.36% 23.74%
Earnings before Tax (EBT) 1 39.8 72.1 83.1 244.6 40.5 55.1 45.8 78.5 92.4 54.9 58.9 122.2 95.1
Net income 1 32.8 57.3 66.1 194.5 31.7 43.8 36.4 61.4 75.1 43.8 45.04 84.45 73.68
Net margin 11.86% 21.18% 23.3% 39.55% 10.76% 15.76% 12.57% 20.39% 23.39% 14.2% 14.05% 23.12% 18.69%
EPS 2 0.2300 0.4100 0.4700 1.380 0.2300 0.3100 0.2600 0.4400 0.5400 0.3100 0.3209 0.6013 0.5250
Dividend per Share 1.500 - - - 1.600 - - - 1.620 - - - -
Announcement Date 10/02/22 28/04/22 15/07/22 20/10/22 09/02/23 27/04/23 17/07/23 26/10/23 13/02/24 25/04/24 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 93.3 - 26.2 -
Net Cash position 1 139 186 108 119 - 1.92 - 1.74
Leverage (Debt/EBITDA) - - - - 0.2858 x - 0.0712 x -
Free Cash Flow 1 228 251 130 325 53.4 177 201 217
ROE (net income / shareholders' equity) 25.8% 29.1% 26.2% 42.2% 24.1% 27.2% 26.6% 35.1%
ROA (Net income/ Total Assets) 18.4% 29.1% 17.4% 26.7% 14.7% 15.3% 14% 15.5%
Assets 1 1,091 755.4 1,115 1,309 1,471 1,586 1,767 2,086
Book Value Per Share 2 5.550 5.210 5.320 6.480 6.340 6.500 6.560 7.240
Cash Flow per Share 2 1.930 2.130 1.540 3.090 0.8500 2.230 2.000 2.800
Capex 1 42.6 48.5 85.4 73.1 117 80.9 79.1 88.5
Capex / Sales 4.05% 4.5% 8.2% 5.45% 9.82% 5.88% 5.44% 5.47%
Announcement Date 05/02/20 09/02/21 10/02/22 09/02/23 13/02/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Orion Oyj

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
39.87 EUR
Average target price
38.2 EUR
Spread / Average Target
-4.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.19% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+45.45% 654B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.09% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.92% 337B
ABBVIE INC. Stock AbbVie Inc.
+10.18% 302B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.26% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+2.41% 229B
NOVARTIS AG Stock Novartis AG
+13.31% 219B
AMGEN INC. Stock Amgen Inc.
+10.86% 171B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ORNBV Stock
  4. ORNAV Stock
  5. Financials Orion Oyj